The National Comprehensive Cancer Network (NCCN) guidelines (4) and the 2015 American Thyroid Association (ATA) guidelines (5) for adult thyroid cancer recommend the use of molecular markers such as BRAF, RAS, and RET/PTC to supplement the diagnosis of benign and malignant thyroid nodules that cannot be accurately identified through fine needle aspiration biopsy (FNAB). The gene discussed is BRAF; the disease is thyroid gland carcinoma.